Zhangxin Wu

Peking University

Papers

1

Total Citations

2

H-Index

1

About

Dr. Zhangxin Wu is a pioneering surgeon–researcher at the forefront of robotic gynecologic oncology, whose work is reshaping minimally invasive cancer surgery. His primary research focuses on the clinical validation and comparative effectiveness of novel surgical robotic systems, with a particular emphasis on improving outcomes for patients with endometrial and other gynecologic malignancies. Dr. Wu’s most notable contribution is leading the first multi-center, randomized, noninferiority trial comparing the KangDuo Surgical Robot-01 (KD-SR-01) against the established da Vinci Xi system for endometrial cancer staging. This landmark study, published in 2025, provides rigorous evidence that the domestically developed KD-SR-01 is both safe and effective, offering a viable alternative to the global standard. While his most-cited paper currently holds 2 citations, its recent publication signals its emerging impact as a foundational reference in surgical robotics. Dr. Wu’s work is critical for expanding access to advanced robotic surgery, lowering costs, and fostering innovation in surgical technology. His achievements position him as a key figure in the global transition toward more equitable, high-tech cancer care.

Research Focus

Key Achievements

1
H-Index
1
Papers
2
Total Citations
2
Avg Citations/Paper
🏆 Most Cited Paper
Comparing the KangDuo Surgical Robot-01 and da Vinci Xi system for endometrial cancer surgery: a multi-center, randomized, parallel-controlled, noninferiority trial
2 citations · 2025
📈 Most Prolific Year: 2025 (1 Papers)
🤝 Key Collaborators: 12
🏛 Institutions: Peking University

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago